Published in Cancer Weekly, June 29th, 1998
It's far too soon to know if Merck & Co.'s experimental vaccine, described at a biotechnology meeting, will work. The company is in the first stage of testing, to make sure the vaccine is safe enough to study in large numbers of women. But it's a long-awaited step.
"We have an exciting opportunity," said Dr. Katherin Jansen, Merck, as she reported that the vaccine seemed highly effective in animals.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.